Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys-Reference-Cited by-同舟云学术

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Published:2016-09-09 Issue:6304 Volume:353 Page:1129-1132
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Abbink Peter¹,Larocca Rafael A.¹,De La Barrera Rafael A.²,Bricault Christine A.¹,Moseley Edward T.¹,Boyd Michael¹,Kirilova Marinela¹,Li Zhenfeng¹,Ng’ang’a David¹,Nanayakkara Ovini¹,Nityanandam Ramya¹,Mercado Noe B.¹,Borducchi Erica N.¹,Agarwal Arshi¹,Brinkman Amanda L.¹,Cabral Crystal¹,Chandrashekar Abishek¹,Giglio Patricia B.¹,Jetton David¹,Jimenez Jessica¹,Lee Benjamin C.¹,Mojta Shanell¹,Molloy Katherine¹,Shetty Mayuri¹,Neubauer George H.¹,Stephenson Kathryn E.¹,Peron Jean Pierre S.³,Zanotto Paolo M. de A.³,Misamore Johnathan⁴,Finneyfrock Brad⁴,Lewis Mark G.⁴,Alter Galit⁵,Modjarrad Kayvon²⁶,Jarman Richard G.²,Eckels Kenneth H.²,Michael Nelson L.²,Thomas Stephen J.²,Barouch Dan H.¹⁵

Affiliation:

1. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

2. Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.

3. University of São Paulo, São Paulo 05508-000, Brazil.

4. Bioqual, Rockville, MD 20852, USA.

5. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

6. Henry M. Jackson Foundation, Bethesda, MD 20817, USA.

Abstract

Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge. These data support the rapid clinical development of ZIKV vaccines for humans.

Funder

Henry M. Jackson Foundation

National Institutes of Health

Ragon Institute of MGH, MIT, and Harvard

Sao Paulo Research Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference30 articles.

1. Zika Virus in the Americas — Yet Another Arbovirus Threat

2. Zika Virus